Clinical Trials Logo

Chronic Allograft Nephropathy clinical trials

View clinical trials related to Chronic Allograft Nephropathy.

Filter by:

NCT ID: NCT05682313 Completed - Clinical trials for Chronic Allograft Nephropathy

Validity of Strain Elastography for the Evaluation of Chronic Allograft Nephropathy

Start date: January 7, 2021
Phase: N/A
Study type: Interventional

Chronic allograft nephropathy is one of dreaded complication of kidney transplant. It is one of the major determinants of long term graft survival. There are a number of factors that can contribute to chronic allograft nephropathy including chronic use of calcineurin inhibitors. Renal biopsy is the investigation of choice to detect chronic renal allograft nephropathy. renal biopsy has a number of complications . This includes infection and bleeding. The non invasive renal sono-elastography (strain and Shear Wave Imaging) technique has shown very good yield of detecting and scoring fibrosis. In this study our aim is to determine the sensitivity and specificity of ( strain sono-elastography) in the detection and classifying of chronic allograft nephropathy as compared to transcutaneous renal biops

NCT ID: NCT01346397 Recruiting - Clinical trials for Chronic Allograft Nephropathy

Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation

RSCS-Campath
Start date: September 2010
Phase: N/A
Study type: Observational [Patient Registry]

After Campath induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates. Patients will be followed including protocol biopsy at 1, 12, 36, 60 month posttransplant, regular nuclein acid testing (NAT) for cytomegalovirus (CMV), Epstein-Barr virus (EBV) and BK virus (BKV) in urine and blood. The investigation is undertaken to clarify the reason for equal survival rates for patients on cyclosporine and tacrolimus despite the lower rejection rate on tacrolimus.

NCT ID: NCT01265615 Completed - Clinical trials for Cardiorenal Syndrome

Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

Start date: October 2009
Phase: Phase 4
Study type: Interventional

We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (CRS). We assume that paricalcitol can have some advantages if compare with calcitriol or cholecalciferol due to absence of calcemic and phosphatemic complications alongside with great beneficial potential.

NCT ID: NCT01056835 Completed - Clinical trials for Chronic Allograft Nephropathy

Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy

Start date: June 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of Prostaglandin I2 analogue use on the development of chronic allograft nephropathy and changes in allograft function in prevalent renal transplant recipients

NCT ID: NCT00999258 Recruiting - Clinical trials for Glomerular Filtration Rate

Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

Start date: September 2009
Phase: Phase 4
Study type: Interventional

The objective of this study is to examine the effect on allograft function and histology of converting African American renal transplant recipients with chronic allograft nephropathy (CAN) from a tacrolimus-based regimen to a sirolimus-based maintenance immunosuppression regimen. The investigators hypothesize that the conversion from tacrolimus to sirolimus in African American renal recipients will stabilize or improve renal allograft function, and stabilize the histological progression of CAN. This conversion will have the potential to prolong long-term graft survival in African American renal transplant patients. GFR measurements, histological parameters on the allograft biopsy, as well as patient and graft survival, incidence of acute rejection, and specific side effects will be monitored and compared between the sirolimus conversion group and the patients who will be maintained on tacrolimus.

NCT ID: NCT00975000 Completed - Clinical trials for Chronic Kidney Disease

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Start date: December 3, 2009
Phase: Phase 3
Study type: Interventional

Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck. Patients with HPT can develop bone disease (osteodystrophy). This bone disease can cause bone pain, fractures, and poor formation of red blood cells. Other problems from HPT may include increases in blood levels of calcium (hypercalcemia) and low blood levels of phosphorus (hypophosphatemia). The high calcium levels may cause calcium to deposit in body tissues. Calcium deposits can cause arthritis (joint pain and swelling), muscle inflammation, itching, gangrene (death of soft tissue), heart and lung problems or kidney transplant dysfunction (worsening of kidney transplant function). The purpose of this study is to evaluate the effects of cinacalcet (Sensipar/Mimpara) on high calcium levels in the blood in patients with HPT after a kidney transplant.

NCT ID: NCT00659620 Not yet recruiting - Kidney Transplant Clinical Trials

Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Mesenchymal Stem Cell (MSC) have been shown to have immunosuppressive and repairing properties. the investigators will infuse expanded MSC into patients who develop Chronic Allograft Nephropathy. The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function.

NCT ID: NCT00568477 Terminated - Clinical trials for Renal Transplantation

Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation

Rituximab 2006
Start date: December 2007
Phase: Phase 2
Study type: Interventional

To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.

NCT ID: NCT00541814 Recruiting - Clinical trials for Chronic Allograft Nephropathy

Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function

CNIM-SRT
Start date: October 2007
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to ascertain whether the withdrawal of calcineurin inhibitors (CNI) will lead to less kidney transplant damage when compared with minimisation. The investigators will assess this by comparing the degree of damage on kidney biopsies taken before and after minimisation/withdrawal of CNI.

NCT ID: NCT00007787 Completed - Clinical trials for Kidney Transplantation

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

Start date: April 2000
Phase: N/A
Study type: Interventional

The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment. There have been improvements for patients receiving kidney transplants, yet acute rejection is still a problem. This can lead to kidney failure over time. Patients whose graft fails to function properly in the first week after transplant do not do as well after 5 years as compared to patients without early problems. This study will see if Thymoglobulin, a drug that suppresses the immune system, will improve early graft function.